Patents Represented by Attorney, Agent or Law Firm Mark S. Cohen
-
Patent number: 6835812Abstract: This invention provides isolated nucleic acids of the rat and human p-Hyde gene, analogs, fragments, mutants and variants thereof of the p-Hyde family. The invention provides polypeptides, fusion proteins, chimerics, fusion proteins, antisense molecules, antibodies, and uses thereof. Also, this invention is directed to a method of inducing susceptibility to apoptosis with p-Hyde, a method of suppressing tumor growth with p-Hyde, and a method of treating a subject with cancer with p-Hyde alone or in combination with radiation, chemotherapy, or UV mimetic drugs. The invention also relates to the therapy of human cancers, which have a mutation in the p-Hyde gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates tot the screening of drugs for cancer therapy. Finally the invention relates to the screening o the p-Hyde gene for mutations, which are useful for diagnosing the predisposition to cancer.Type: GrantFiled: May 2, 2000Date of Patent: December 28, 2004Assignee: University of Tennessee Research CorporationInventors: Mitchell S. Steiner, Chiang Wang
-
Patent number: 6814966Abstract: This invention provides a method for treating a subject with glaucoma comprising the steps of administrating a compound or composition which antagonize, inhibits, inactivates, reduce, suppresses, antagonizes, and/or limits the release, synthesis, or production from cells of TNF-&agr; thereby treating the subject with glaucoma.Type: GrantFiled: June 13, 2000Date of Patent: November 9, 2004Assignee: Pharmacia CorporationInventors: Martin B. Wax, Gulgun Tezel
-
Patent number: 6632447Abstract: This invention relates to the chemoprevention of prostate cancer and, more particularly, to a method of suppressing or inhibiting latent prostate cancer comprising administering to a mammalian subject a chemopreventive agent and analogs and metabolites thereof. The chemopreventive agent prevents, prevents recurrence of, suppresses or inhibit prostate carcinogenesis; and treats prostate cancer.Type: GrantFiled: November 8, 2000Date of Patent: October 14, 2003Assignee: The University of Tennessee Research CorporationInventors: Mitchell S. Steiner, Sharan Raghow
-
Patent number: 6569896Abstract: This invention provides a novel class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds which are tissue-selective androgen receptor modulators (SARM), which are useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer. These agents have an unexpected in-vivo activity for an androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. These agents may be active alone or in combination with progestins or estrogens. The invention further provides a novel class of non-steroidal agonist compounds. The invention further provides compositions containing the selective androgen modulator compounds or the non-steroidal agonist compounds and methods of binding an androgen receptor, modulating spermatogenesis, treating and imaging prostate cancer, and providing hormonal therapy for androgen-dependent conditions.Type: GrantFiled: August 23, 2001Date of Patent: May 27, 2003Assignee: The University of Tennessee Research CorporationInventors: James T. Dalton, Duane D. Miller, Donghua Yin, Yali He
-
Patent number: 6531128Abstract: This invention provides a method for treating a subject with glaucoma by administrating a composition containing an agent or molecule which antagonize, inhibits, inactivates, reduce, suppresses, antagonizes, and/or limits the release, synthesis, or production from cells of TNF-&agr; thereby treating the subject with glaucoma.Type: GrantFiled: February 8, 2000Date of Patent: March 11, 2003Assignee: Pharmacia CorporationInventors: Martin B. Wax, Gulgun Tezel
-
Patent number: 6497873Abstract: This invention relates to a composition comprising a recombinant or genetically engineered Rhabdovirus that expresses a Fusion Protein, such as the F protein of the Paramyxovirus SV5 strain. This recombinant Rhabdovirus may express other non-Rhabdovirus attachment proteins and/or an enhancer protein. The invention also relates to methods of making recombinant Rhabdoviruses which express an F Protein. These recombinant compositions can be used for purposes of research, as well as for diagnostic and therapeutic compositions for treatment of diseases.Type: GrantFiled: December 22, 1998Date of Patent: December 24, 2002Assignee: The University of Tennessee Research CorporationInventors: Michael A. Whitt, Clinton S. Robison
-
Patent number: 6492554Abstract: The present invention relates to a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for male hormone therapy such as oral testosterone replacement therapy, treating prostate cancer, imaging prostate cancer.Type: GrantFiled: August 23, 2001Date of Patent: December 10, 2002Assignee: The University of Tennessee Research CorporationInventors: James T. Dalton, Duane D. Miller, Donghua Yin, Yali He
-
Patent number: 6482861Abstract: The present invention relates to an antiandrogen compound and a method of treating prostate cancer in a patient utilizing the compound. The present invention also relates to a pharmaceutical composition which includes the compound.Type: GrantFiled: February 22, 2000Date of Patent: November 19, 2002Assignee: The University of Tennessee Research CorporationInventors: Duane D. Miller, Leonid I. Kirkovsky, James T. Dalton, Arnab Mukherjee
-
Patent number: 6413534Abstract: This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive agent to prevent, prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.Type: GrantFiled: September 12, 2000Date of Patent: July 2, 2002Assignee: The University of Tennessee Research CorporationInventors: Mitchell S. Steiner, Sharan Raghow
-
Patent number: 6413535Abstract: This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive agent to prevent, prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.Type: GrantFiled: September 12, 2000Date of Patent: July 2, 2002Assignee: The University of Tennessee Research CorporationInventors: Mitchell S. Steiner, Sharan Raghow
-
Patent number: 6413533Abstract: This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive agent to prevent, prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.Type: GrantFiled: March 20, 2000Date of Patent: July 2, 2002Assignee: The University of Tennessee Research CorporationInventors: Mitchell S. Steiner, Sharan Raghow
-
Patent number: 6410043Abstract: This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive agent to prevent, prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.Type: GrantFiled: September 12, 2000Date of Patent: June 25, 2002Assignee: The University of Tennessee Research CorporationInventors: Mitchell S. Steiner, Sharan Raghow
-
Patent number: 6338837Abstract: Compositions for inhibiting nematocyst or polar capsule discharge are provided in the form of an effective amount of antihistamine, an effective amount of antihistamine and an effective amount of at least one cation, or an effective amount of at least one cation. The compositions can be in the form of ointments or can be added to the environment surrounding the nematocysts or polar capsules. Methods of inhibiting nematocyst or polar capsule discharge using the compositions of the invention are also provided.Type: GrantFiled: October 8, 1997Date of Patent: January 15, 2002Assignee: Nidaria Technology Ltd.Inventor: Amit Lotan
-
Patent number: 6265448Abstract: This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent, toremifene and analogs or metabolites thereof, to prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having an elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.Type: GrantFiled: May 7, 1999Date of Patent: July 24, 2001Assignee: The University of Tennessee Research CorporationInventors: Mitchell S. Steiner, Sharon Raghow